Topics:
Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University
How would you treat metastatic NSCLC in a non-smoker with bone biopsy showing adenocarcinoma of lung origin but inadequate tissue for mutational panel or PD-L1?
Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would you forego that forgo and consider chemotherapy +/- immunotherapy?
Answer from: Medical Oncologist at Academic Institution
Molecular studies and PDL1 have become standard for patients with advanced/metastatic lung adenocarcinoma. We feel particularly strongly about doing this (molecular studies) in the never smoker, however all adenocarcinomas (and selected squamous cancers) should have this done. Cytology specimens (...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
However, unfortunately, the only FDA approved plasma test is the Roche test for EGFR mutations. This has a reasonable sensitivity for EGFR mutations by about 85% in patients who were untreated but were able to have the tissue biopsy. In a patient with insufficient tissue, the yie...